Evaluation of the Pathobiology of CALR-mutated MPN Cells
Key claim: CALR-mutated MPN cells exhibit distinct pathobiological features that may explain the lower thrombosis risk observed in CALR-mutated patients compared to those with JAK2 mutations.
Abstract
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Why this matters
Thrombosis risk stratification in MPNs is increasingly genotype-driven, with JAK2V617F conferring substantially higher thrombotic risk than CALR mutations across ET and PMF. Mechanistic preclinical evidence explaining this difference supports the rationale for genotype-tailored antithrombotic strategies (e.g., the JAK2-restricted AVAJAK DOAC trial) and informs how CALR-mutated subsets of ET and PMF should be counseled and managed differently from their JAK2-mutated counterparts.